What are the anticipated bone marrow cellularity and M:E ratio in this patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Anticipated Bone Marrow Findings in Acute Promyelocytic Leukemia

The bone marrow in this patient with acute promyelocytic leukemia would be hypercellular with increased M:E ratio (option C).

Clinical Presentation Analysis

The 8-year-old female presents with classic features of acute leukemia:

  • Fatigue and pallor (anemia)
  • Unexplained large bruises (thrombocytopenia)
  • Markedly elevated WBC count (110 × 10³/μL)
  • Peripheral blood showing 53% blasts with Auer rods
  • Presence of immature myeloid cells in peripheral blood (promyelocytes, myelocytes, metamyelocytes)

The presence of Auer rods in blast cells and the high percentage of promyelocytes (12%) strongly suggests acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML).

Bone Marrow Cellularity in Acute Leukemia

In acute myeloid leukemia, the bone marrow is typically hypercellular due to the proliferation of immature myeloid cells. Studies have shown that:

  • The median bone marrow cellularity in AML is >50% without age adjustment 1
  • 63% of patients with AML have hypercellular bone marrow when corrected for age 1
  • Only a small minority of AML cases present with hypocellular marrow 2

M:E Ratio Analysis

The M:E (myeloid to erythroid) ratio would be increased in this case for several reasons:

  1. The peripheral blood shows predominance of myeloid cells (blasts, promyelocytes, myelocytes, metamyelocytes, bands, and segmented neutrophils totaling 93%)

  2. The massive proliferation of myeloid precursors in AML typically crowds out erythroid precursors, leading to an increased M:E ratio

  3. When erythroid precursors constitute less than 50% of bone marrow nucleated cells (which is expected in this case), the percentage of blasts is based on all nucleated cells 2

Specific Findings in Acute Promyelocytic Leukemia

In acute promyelocytic leukemia specifically:

  • The bone marrow is typically hypercellular with a predominance of abnormal promyelocytes
  • The proliferation of myeloid precursors (particularly promyelocytes) leads to an increased M:E ratio
  • Normal hematopoiesis is suppressed, with decreased erythroid precursors

Common Pitfalls to Avoid

  1. Confusing with hypocellular variants: While hypocellular AML exists, it's uncommon and not consistent with this patient's presentation of high WBC count and numerous blasts in peripheral blood

  2. Misinterpreting decreased platelets: The markedly decreased platelets noted on peripheral smear is a feature of bone marrow infiltration by leukemic cells, not an indication of hypocellularity

  3. Overlooking the myeloid nature: The differential clearly shows predominance of myeloid lineage cells (93% myeloid cells vs. 7% lymphocytes), which supports an increased M:E ratio

The combination of hypercellularity and increased M:E ratio (option C) is the most consistent with the clinical and laboratory findings in this patient with features of acute promyelocytic leukemia.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.